Pál Perge1, Ábel Decmann1, Raffaele Pezzani2, Irina Bancos3, Ambrogio Fassina4, Michaela Luconi5, Letizia Canu5, Miklós Tóth1, Marco Boscaro2, Attila Patócs6,7, Peter Igaz8,9. 1. 2nd Department of Medicine, Semmelweis University, 1088, Budapest, Szentkiralyi str. 46., Hungary. 2. Endocrinology Unit, Department of Medicine, University of Padua, Via Ospedale, 105, 35128, Padova, Italy. 3. Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 4. Cytopathology Unit, Department of Medicine, University of Padua, Via Ospedale, 105, 35128, Padova, Italy. 5. Department of Experimental and Clinical Biomedical Sciences, Endocrinology Unit, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. 6. MTA-SE Molecular Medicine Research Group, Hungarian Academy of Sciences and Semmelweis University, 1088, Budapest, Szentkirályi str. 46., Hungary. 7. Lendület-2013 Research Group, Hungarian Academy of Sciences and Semmelweis University, 1088, Budapest, Szentkirályi str. 46., Hungary. 8. 2nd Department of Medicine, Semmelweis University, 1088, Budapest, Szentkiralyi str. 46., Hungary. igaz.peter@med.semmelweis-univ.hu. 9. MTA-SE Molecular Medicine Research Group, Hungarian Academy of Sciences and Semmelweis University, 1088, Budapest, Szentkirályi str. 46., Hungary. igaz.peter@med.semmelweis-univ.hu.
Abstract
PURPOSE: Circulating microRNAs (miRNA) have been described in patients with adrenocortical tumors, but the expression of miRNAs in non-functioning and cortisol-producing tumors has not been yet compared. Therefore, the objective of this study was to evaluate the expression of plasma extracellular vesicle (EV)-associated microRNAs in patients with non-functioning adrenocortical adenoma (NFA), cortisol-producing adrenocortical adenoma (CPA) and cortisol-producing adrenocortical carcinoma (CP-ACC). METHODS: Preoperative plasma EV samples of 13 NFAs, 13 CPAs and 9 CP-ACCs were subjected to extracellular vesicle isolation. miRNAs were investigated by targeted quantitative real-time PCR normalized to cel-miR-39 as reference. Five miRNAs have been selected for this analysis based on the previous studies including hsa-miR-22-3p, hsa-miR-27a-3p, hsa-miR-210-3p, hsa-miR-320b and hsa-miR-375. RESULTS: We have observed significant overrepresentation of three miRNAs in both CPA and CP-ACC relative to NFA: hsa-miR-22-3p (p < 0.01 and p < 0.0001, respectively), hsa-miR-27a-3p (p < 0.05 in both comparisons) and hsa-miR-320b (p < 0.05 and p < 0.0001, respectively). Hsa-miR-320b has been significantly overrepresented in CP-ACC relative to CPA (p < 0.01). Hsa-miR-210-3p turned out to be significantly overrepresented only in CP-ACC compared to NFA (p < 0.05). Significant correlation was revealed between circulating miRNA concentrations and urinary free cortisol values for hsa-miR-22-3p, hsa-miR-27a-3p and hsa-miR-320b (p < 0.0001 for all) and cortisol after low-dose dexamethasone test for hsa-miR-22-3p and hsa-miR-320b (p < 0.05). Hsa-miR-27a-3p has been significantly stimulated by low-dose dexamethasone test (p < 0.05). CONCLUSIONS: EV-associated miRNAs are differentially expressed in different non-functioning and cortisol-producing adrenocortical tumors.
PURPOSE: Circulating microRNAs (miRNA) have been described in patients with adrenocortical tumors, but the expression of miRNAs in non-functioning and cortisol-producing tumors has not been yet compared. Therefore, the objective of this study was to evaluate the expression of plasma extracellular vesicle (EV)-associated microRNAs in patients with non-functioning adrenocortical adenoma (NFA), cortisol-producing adrenocortical adenoma (CPA) and cortisol-producing adrenocortical carcinoma (CP-ACC). METHODS: Preoperative plasma EV samples of 13 NFAs, 13 CPAs and 9 CP-ACCs were subjected to extracellular vesicle isolation. miRNAs were investigated by targeted quantitative real-time PCR normalized to cel-miR-39 as reference. Five miRNAs have been selected for this analysis based on the previous studies including hsa-miR-22-3p, hsa-miR-27a-3p, hsa-miR-210-3p, hsa-miR-320b and hsa-miR-375. RESULTS: We have observed significant overrepresentation of three miRNAs in both CPA and CP-ACC relative to NFA: hsa-miR-22-3p (p < 0.01 and p < 0.0001, respectively), hsa-miR-27a-3p (p < 0.05 in both comparisons) and hsa-miR-320b (p < 0.05 and p < 0.0001, respectively). Hsa-miR-320b has been significantly overrepresented in CP-ACC relative to CPA (p < 0.01). Hsa-miR-210-3p turned out to be significantly overrepresented only in CP-ACC compared to NFA (p < 0.05). Significant correlation was revealed between circulating miRNA concentrations and urinary free cortisol values for hsa-miR-22-3p, hsa-miR-27a-3p and hsa-miR-320b (p < 0.0001 for all) and cortisol after low-dose dexamethasone test for hsa-miR-22-3p and hsa-miR-320b (p < 0.05). Hsa-miR-27a-3p has been significantly stimulated by low-dose dexamethasone test (p < 0.05). CONCLUSIONS: EV-associated miRNAs are differentially expressed in different non-functioning and cortisol-producing adrenocortical tumors.
Authors: Maria Angelica Cortez; Carlos Bueso-Ramos; Jana Ferdin; Gabriel Lopez-Berestein; Anil K Sood; George A Calin Journal: Nat Rev Clin Oncol Date: 2011-06-07 Impact factor: 66.675
Authors: Niels H H Heegaard; Aaron J Schetter; Judith A Welsh; Mitsuhiro Yoneda; Elise D Bowman; Curtis C Harris Journal: Int J Cancer Date: 2011-08-26 Impact factor: 7.396
Authors: O Chabre; R Libé; G Assie; O Barreau; J Bertherat; X Bertagna; J-J Feige; N Cherradi Journal: Endocr Relat Cancer Date: 2013-07-05 Impact factor: 5.678
Authors: Martin Fassnacht; Sarah Johanssen; Marcus Quinkler; Peter Bucsky; Holger S Willenberg; Felix Beuschlein; Massimo Terzolo; Hans-Helge Mueller; Stefanie Hahner; Bruno Allolio Journal: Cancer Date: 2009-01-15 Impact factor: 6.860
Authors: Wiebke Arlt; Michael Biehl; Angela E Taylor; Stefanie Hahner; Rossella Libé; Beverly A Hughes; Petra Schneider; David J Smith; Han Stiekema; Nils Krone; Emilio Porfiri; Giuseppe Opocher; Jerôme Bertherat; Franco Mantero; Bruno Allolio; Massimo Terzolo; Peter Nightingale; Cedric H L Shackleton; Xavier Bertagna; Martin Fassnacht; Paul M Stewart Journal: J Clin Endocrinol Metab Date: 2011-09-14 Impact factor: 5.958
Authors: Pál Perge; Henriett Butz; Raffaele Pezzani; Irina Bancos; Zoltán Nagy; Krisztina Pálóczi; Gábor Nyírő; Ábel Decmann; Erna Pap; Michaela Luconi; Massimo Mannelli; Edit I Buzás; Miklós Tóth; Marco Boscaro; Attila Patócs; Peter Igaz Journal: Sci Rep Date: 2017-07-14 Impact factor: 4.379